English
Regional settings| Spread | 0.13 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 31.22 |
| Open | 31.15 |
| 1-Year Change | -13.76% |
| Day's Range | 31.15 - 32.23 |
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that enables consumers to prevent or treat conditions that can be self-managed. The Company operates through two segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises consumer self-care business (OTC, infant formula, and oral self-care categories, and contract manufacturing) in the United States (U.S) and Canada. CSCA segment products sold under brands, such as Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees. The CSCI segment comprises consumer self-care business primarily branded in Europe and Australia, store brand business in the United Kingdom and parts of Europe and Asia. The CSCI segment primarily focuses on building local and regional brands sold through merchandisers, drug stores, pharmacies, and e-commerce channels.
BRIEF: For the fiscal year ended 31 December 2021, Perrigo Company PLC revenues increased 1% to $4.14B. Net loss before extraordinary items totaled $130.9M vs. income of $44.2M. Revenues reflect CSCI segment increase of 4% to $1.45B, CSCA segment remaining flat at $2.69B, Europe segment increase of 3% to $1.39B. Net loss reflects CSCA segment income decrease of 56% to $206.5M. Dividend per share increased from $0.90 to $0.96.
Common Stock no Par, 08/11, 200M auth., 92,797,375 issd. Insiders own 7.05%. IPO: 10/93, 13Mshares @ $31 by J.P. Morgan Securities Inc. 8/93, 2-for-1 stock split. FY'02 & Q's are restated. FY'03 & '04 Summ. Q's reflect the reclassification. FY'04 Q's are reclassified.
